Cargando…

A case report in cardiovascular magnetic resonance: the contrast agent matters in amyloid

BACKGROUND: Cardiac amyloidosis is a progressive but underdiagnosed and underappreciated cause of heart failure. In the last few years, cardiovascular magnetic resonance (CMR) has become the gold standard for non invasive diagnosis of cardiac amyloidosis with the characteristic subendocardial late g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fontana, Marianna, Treibel, Thomas A., Martinez-Naharro, Ana, Rosmini, Stefania, Kwong, Raymond Y., Gillmore, Julian D., Hawkins, Philip N., Moon, James C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5219753/ https://www.ncbi.nlm.nih.gov/pubmed/28061823 http://dx.doi.org/10.1186/s12880-016-0173-5

Ejemplares similares

Occult senile cardiac amyloid in severe calcific aortic stenosis is not rare and has a poor prognosis: a 146 patient CMR biopsy study
por: Treibel, Thomas A, et al.
Publicado: (2016)

Acute changes in cardiac structural and tissue characterisation parameters following haemodialysis measured using cardiovascular magnetic resonance
por: Kotecha, Tushar, et al.
Publicado: (2019)

Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis
por: Fontana, Marianna, et al.
Publicado: (2015)

Impact of microvascular obstruction on semiautomated techniques for quantifying acute and chronic myocardial infarction by cardiovascular magnetic resonance
por: Bulluck, Heerajnarain, et al.
Publicado: (2016)

Redefining viability by cardiovascular magnetic resonance in acute ST-segment elevation myocardial infarction
por: Bulluck, Heerajnarain, et al.
Publicado: (2017)

Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment
por: Martinez-Naharro, Ana, et al.
Publicado: (2022)

Defining left ventricular remodeling following acute ST-segment elevation myocardial infarction using cardiovascular magnetic resonance
por: Bulluck, Heerajnarain, et al.
Publicado: (2017)

AL and ATTR cardiac amyloid are different: native T1 mapping and ECV detect different biology
por: Fontana , Marianna, et al.
Publicado: (2014)

Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy
por: Law, Steven, et al.
Publicado: (2022)

Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis
por: Treibel, Thomas A., et al.
Publicado: (2015)

Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy
por: Fontana, Marianna, et al.
Publicado: (2023)

Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis
por: Patel, Rishi K., et al.
Publicado: (2022)

Cardiac amyloid burden assessment by T1 mapping predicts survival in patients with systemic AL amyloidosis - a 2 year follow-up study
por: Banypersad, Sanjay M, et al.
Publicado: (2014)

Incidence of left ventricular thrombi in reperfused STEMI patients detected by contrast-enhanced CMR
por: Bulluck, Heerajnarain, et al.
Publicado: (2015)

Rare Forms of Cardiac Amyloidosis: Diagnostic Clues and Phenotype in Apo AI and AIV Amyloidosis
por: Ioannou, Adam, et al.
Publicado: (2023)

Precision measurement of cardiac structure and function in cardiovascular magnetic resonance using machine learning
por: Davies, Rhodri H., et al.
Publicado: (2022)

Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria
por: Sharpley, Faye A., et al.
Publicado: (2020)

Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis
por: Ravichandran, Sriram, et al.
Publicado: (2022)

Tracking Multiorgan Treatment Response in Systemic AL-Amyloidosis With Cardiac Magnetic Resonance Derived Extracellular Volume Mapping
por: Ioannou, Adam, et al.
Publicado: (2023)

CMR findings in high endurance veteran athletes - a 247 subject study
por: Maestrini, Viviana, et al.
Publicado: (2016)

Five novel TTR variants: associated phenotypes and structural consequences
por: Rowczenio, Dorota, et al.
Publicado: (2015)

Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib
por: Ravichandran, Sriram, et al.
Publicado: (2021)

Cardiovascular magnetic resonance-guided right heart catheterization in a conventional CMR environment – predictors of procedure success and duration in pulmonary artery hypertension
por: Knight, Daniel S., et al.
Publicado: (2019)

Spotting senile systemic amyloidosis: why we miss it
por: Fontana, Marianna, et al.
Publicado: (2015)

Cardiac involvement in cardiac AL amyloidosis as measured by equilibrium contrast cardiovascular magnetic resonance
por: Banypersad, Sanjay M, et al.
Publicado: (2012)

The effects of extracellular contrast agent (Gadobutrol) on the precision and reproducibility of cardiovascular magnetic resonance feature tracking
por: Kuetting, Daniel L. R., et al.
Publicado: (2016)

Transthyretin cardiac amyloidosis
por: Porcari, Aldostefano, et al.
Publicado: (2022)

RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis
por: Ioannou, Adam, et al.
Publicado: (2023)

Myocardial Extracellular Volume Quantification by Cardiovascular Magnetic Resonance and Computed Tomography
por: Scully, Paul R., et al.
Publicado: (2018)

The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis
por: Cohen, Oliver C., et al.
Publicado: (2020)

Cardiac transplantation in transthyretin amyloid cardiomyopathy: Outcomes from three decades of tertiary center experience
por: Razvi, Yousuf, et al.
Publicado: (2023)

An instantaneous ECV with no blood sampling: using native blood T1 for hematocrit is as good as standard ECV
por: Treibel, Thomas A, et al.
Publicado: (2015)

Society for Cardiovascular Magnetic Resonance (SCMR) guidelines for reporting cardiovascular magnetic resonance examinations
por: Hundley, W. Gregory, et al.
Publicado: (2022)

Imaging-Guided Treatment for Cardiac Amyloidosis
por: Ioannou, Adam, et al.
Publicado: (2022)

Myocardial iron quantification using T2* and native T1mapping - a 250 patient study
por: Abdel-Gadir, Amna, et al.
Publicado: (2015)

Contrast agents in dynamic contrast-enhanced magnetic resonance imaging
por: Yan, Yuling, et al.
Publicado: (2017)

Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage
por: Law, Steven, et al.
Publicado: (2020)

Effects of gadolinium contrast agent on aortic blood flow and myocardial strain measurements by phase-contrast cardiovascular magnetic resonance
por: Hedström, Erik, et al.
Publicado: (2010)

Quality of life in ATTR amyloidosis
por: Lane, Thirusha, et al.
Publicado: (2015)

Blood correction reduces variability and gender differences in native myocardial T1 values at 1.5 T cardiovascular magnetic resonance – a derivation/validation approach
por: Nickander, Jannike, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7socvu0qip97het27es9hpbtrh